Primary Sjogren’s Syndrome (pSS) is a classic, immunemediated, condition of unknown aetiology characterized by focal lymphocytic infiltration of exocrine glands [1]. Patients characteristically complain of drying of the eyes and mucosal surfaces along with fatigue and arthralgia. There is an association with autoimmune thyroid disease, coeliac disease and primary biliary cirrhosis. Systemic features include inflammatory arthritis, scLE, immune thrombocytopenia (ITP), vasculitis with purpura, salivary gland inflammation, neuropathies, interstitial lung disease (ILD) and a 510% lifetime risk of B cell lymphoma [2, 3]. This guideline reviews the treatment of the glandular and systemic features of pSS The management of the glandular features includes conserving, replacing and stimulating secretions. Systemic features may require system-specific therapy and immunomodulatory treatment. Holistic management is important and many patients benefit from non-pharmacological therapies and general support.

The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome / Price, Elizabeth J.; Rauz, Saaeha; Tappuni, Anwar R.; Sutcliffe, Nurhan; Hackett, Katie L.; Barone, Francesca; Granata, Guido; Ng, Wan-Fai; Fisher, Benjamin A.; Bombardieri, Michele; Astorri, Elisa; Empson, Ben; Larkin, Genevieve; Crampton, Bridget; Bowman, Simon J.. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 56:10(2017), pp. e24-e48. [10.1093/rheumatology/kex166]

The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome

Granata, Guido;Astorri, Elisa;
2017

Abstract

Primary Sjogren’s Syndrome (pSS) is a classic, immunemediated, condition of unknown aetiology characterized by focal lymphocytic infiltration of exocrine glands [1]. Patients characteristically complain of drying of the eyes and mucosal surfaces along with fatigue and arthralgia. There is an association with autoimmune thyroid disease, coeliac disease and primary biliary cirrhosis. Systemic features include inflammatory arthritis, scLE, immune thrombocytopenia (ITP), vasculitis with purpura, salivary gland inflammation, neuropathies, interstitial lung disease (ILD) and a 510% lifetime risk of B cell lymphoma [2, 3]. This guideline reviews the treatment of the glandular and systemic features of pSS The management of the glandular features includes conserving, replacing and stimulating secretions. Systemic features may require system-specific therapy and immunomodulatory treatment. Holistic management is important and many patients benefit from non-pharmacological therapies and general support.
2017
Guideline; Management; Sicca; Sjögren's; Adult; Candidiasis, Oral; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Oral Hygiene; Sialadenitis; Sjogren's Syndrome; Rheumatology; Pharmacology (medical)
01 Pubblicazione su rivista::01a Articolo in rivista
The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome / Price, Elizabeth J.; Rauz, Saaeha; Tappuni, Anwar R.; Sutcliffe, Nurhan; Hackett, Katie L.; Barone, Francesca; Granata, Guido; Ng, Wan-Fai; Fisher, Benjamin A.; Bombardieri, Michele; Astorri, Elisa; Empson, Ben; Larkin, Genevieve; Crampton, Bridget; Bowman, Simon J.. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 56:10(2017), pp. e24-e48. [10.1093/rheumatology/kex166]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1289635
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 25
social impact